相关实验视频

Updated: Sep 14, 2025

A Protocol to Acquire the Degenerative Tenocyte from Humans

A Protocol to Acquire the Degenerative Tenocyte from Humans

Published on: June 9, 2018

格利布里德通过抑制性肌病的NLRP3炎症酶来加速肌愈合的过程

WeiYi Chen^1,2,3, WanQing Qi^1,2,3, MengYang Jia^1,2,3

¹Department of Sports Medicine, Xinhua Hospital affiliated to Dalian University, Dalian, Liaoning, China.

The American journal of sports medicine

|July 21, 2025

概括

格利布里德通过抑制NLRP3炎症酶途径,有效地减少了肌病中的退化和沉积. 这表明,glyburide可能会加速肌愈合,并提供一种新的治疗选择.

科学领域:

生物医学科学生物医学科学
分子生物学分子生物学
整形外科整形外科整形外科

背景情况:

性肌病症涉及NLRP3炎症酶激活由性晶体,驱动炎症和进展.
低级NLRP3炎症酶活性可能促进肌原蛋白再生.
低血糖药物格利布里德是一种已知的NLRP3炎症酶的抑制剂.

研究的目的:

为了评估glyburide在性肌病的治疗潜力.
阐明NLRP3炎症酶在糖对肌愈合的影响中的作用.

主要方法:

建立了由原酶诱导的状肌病症的老鼠模型.
鼠被用DMSO,赛莱科克西布或糖化物治疗.
肌愈合通过形态和组织学分析进行了评估;NLRP3炎症组分表达 (NLRP3,ASC,caspase-1,IL-1β,IL-18) 通过RT-qPCR和西方斑点测量量.

主要成果:

与对照组和赛莱科克西布组相比,草甘治疗显著减少了阿基勒斯退化和沉积.
在glyburide组中,NLRP3炎症组分 (NLRP3,ASC,caspase-1,IL-1β,IL-18) 在mRNA和蛋白质水平的表达显著下降.

结论:

格利布里德有效地抑制了状肌病的NLRP3炎症酶途径.
在这种情况下,GLYBURIDE显示出加速肌愈合的治疗潜力.
格利布里德 (Glyburide) 是一种有前途的新疗法策略,用于治疗状肌病.

关键词:

类似NOD的受体蛋白3炎症体炎症体状肌病症是一种状肌病.甘化的使用方法这是一种炎症炎症炎症炎症.肌再生肌再生

更多相关视频

Evaluation of Stem Cell Therapies in a Bilateral Patellar Tendon Injury Model in Rats

Evaluation of Stem Cell Therapies in a Bilateral Patellar Tendon Injury Model in Rats

Published on: March 30, 2018

Author Spotlight: Integrating Mechanical and Biological Analysis in Tendinopathy Research

Author Spotlight: Integrating Mechanical and Biological Analysis in Tendinopathy Research

Published on: March 1, 2024

相关概念视频

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...